Horizon Pharma Rheumatology LLC – Trademark Portfolio
Entity Type: 16
Horizon Pharma Rheumatology LLC holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include MIGERGOT and KRYSTEXXA. The owner is based in LAKE FOREST, IL.
150 S SAUNDERS RD.
SUITE 130
LAKE FOREST, IL 60045
Showing of trademarks Trademarks
Trademark Classifications
Horizon Pharma Rheumatology LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Horizon Pharma Rheumatology LLC have?
Horizon Pharma Rheumatology LLC has 5 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned, 2 cancelled.
What trademark classes does Horizon Pharma Rheumatology LLC file in?
Horizon Pharma Rheumatology LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Horizon Pharma Rheumatology LLC's most well-known trademarks?
Horizon Pharma Rheumatology LLC's registered trademark portfolio includes well-known marks such as MIGERGOT and KRYSTEXXA. These are among 2 currently registered trademarks in the portfolio.
What is Horizon Pharma Rheumatology LLC's trademark registration success rate?
Horizon Pharma Rheumatology LLC has a 40% trademark registration rate, with 2 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.